STRATA Skin Sciences, Inc.
SSKNOTCHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $30.7M | $33.6M | $33.4M | $36.2M | $30.0M | $23.1M |
| Operating income | −$1.7M | −$2.9M | −$8.6M | −$4.6M | −$4.4M | −$4.1M |
| Net income | −$2.1M | −$3.4M | −$10.8M | −$5.5M | −$2.7M | −$4.4M |
| Total assets | $33.0M | $39.2M | $42.0M | $52.3M | $46.6M | $46.8M |
| Total liabilities | $30.1M | $29.8M | $29.3M | $30.4M | $21.2M | $20.9M |
| Equity | $3.0M | $9.4M | $12.7M | $21.8M | $25.4M | $25.9M |
| EPS (diluted) | $-0.51 | $-0.10 | $-3.10 | $-0.16 | — | $-0.13 |
| Shares out. | 4.2M | 35.1M | 34.9M | 34.7M | 33.8M | 33.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −5.6%
- Net margin
- −6.9%
- Return on equity
- −71.2%
- Return on assets
- −6.4%
- Return on capital (ROCE)
- −8.8%
- Liabilities / assets
- 91.0%
- Debt / equity
- 10.09×
- Book value / share
- $0.71
- Revenue growth (YoY)
- −8.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -24.54distress
- Accruals / assets
- 2.0%clean
- Beneish M-Score
- -2.73normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 5 warning● 1 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 14, 2019
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2019
- NT 10-Qmissed a reporting deadline ↗May 16, 2019
- NT 10-Kmissed a reporting deadline ↗Apr 2, 2019
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Cvi Investments, Inc.Passive (13G)Nov 7, 2025
- Accelmed Partners, L.P.Activist (13D)Sep 5, 2025
- Lincoln Alternative Strategies LlcPassive (13G)Sep 4, 2025
- Nantahala Capital Management, LlcPassive (13G)Nov 14, 2024
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 57,938 | 2.7 | +2.0% |
| Apr 30, 2026 | 56,822 | 2.9 | -3.7% |
| Apr 15, 2026 | 58,988 | 1.5 | -16.1% |
| Mar 31, 2026 | 70,266 | 1.1 | -63.5% |
| Mar 13, 2026 | 192,345 | 2.1 | -36.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Delisting / listing-standard notice · Other material eventFeb 11, 2026
- Regulation FD disclosureDec 17, 2025
- Shareholder voteDec 10, 2025
- Results of operations · Regulation FD disclosureNov 13, 2025
- Other material eventOct 16, 2025
- Delisting / listing-standard noticeOct 14, 2025
- Regulation FD disclosureSep 4, 2025
- Entered a material agreement · Regulation FD disclosureSep 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-KMar 26, 2026
- EFFECTMar 4, 2026
- EFFECTMar 4, 2026
- EFFECTMar 4, 2026
- 15-12GFORM 15-12GMar 2, 2026
- POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3Feb 27, 2026
- POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3Feb 27, 2026
- POS AMPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3Feb 27, 2026
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 27, 2026
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 27, 2026
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 27, 2026
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 27, 2026
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 27, 2026
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 27, 2026
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8Feb 27, 2026
Event-driven situations (2)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.